Benjamin Hohl
CHIEF FINANCIAL OFFICER · 6 filings · Latest: Sep 17, 2026
Enliven Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ELVN | Hohl Benjamin | — | Jan 3, 2025 | Proposed Sale | $23.90 | 1,000 | $23.9K | — | |
ELVN | Hohl Benjamin | — | Dec 27, 2024 | Proposed Sale | $22.71 | 4,250 | $96.5K | — | |
ELVN | Hohl Benjamin | — | Oct 18, 2024 | Proposed Sale | $28.02 | 13,000 | $364.3K | — | |
ELVN | Hohl Benjamin | — | Oct 1, 2024 | Proposed Sale | $25.54 | 12,009 | $306.7K | — | |
ELVN | Hohl Benjamin | — | Sep 30, 2024 | Proposed Sale | $24.13 | 491 | $11.8K | — | |
ELVN | Hohl Benjamin | — | Apr 28, 2025 | Proposed Sale | $18.21 | 3,250 | $59.2K | — |
← Previous
Page 2 of 2